Details for Patent: 11,564,926

Which drugs does patent 11,564,926 protect, and when does it expire?

Patent 11,564,926 protects REZDIFFRA and is included in one NDA.

This patent has eighty-seven patent family members in thirty countries.

Summary for Patent: 11,564,926

Title:	Methods of synthesizing thyroid hormone analogs and polymorphs thereof
Abstract:	The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.
Inventor(s):	II D. Keith Hester, Robert J. Duguid, Martha J. Kelly, Anna Chasnoff, Gang Dong, Edwin L. Crow, Lianhe Shu, Ping Wang, Duk Soon Choi
Assignee:	Hoffmann La Roche Inc , Madrigal Pharmaceuticals Inc
Application Number:	US17/118,706
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 11,564,926

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-001	Mar 14, 2024		RX	Yes	No			Y	Y		TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-002	Mar 14, 2024		RX	Yes	No			Y	Y		TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-003	Mar 14, 2024		RX	Yes	Yes			Y	Y		TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)

International Family Members for US Patent 11,564,926

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	4406594		CA 2026 00008	Denmark
European Patent Office	4406594		301369	Netherlands
European Patent Office	4406594		PA2026507	Lithuania
European Patent Office	4406594		C20265007	Finland
European Patent Office	4406594		2026C/705	Belgium
Argentina	092872
Argentina	132930